StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note published on Thursday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
NASDAQ TTNP opened at $4.06 on Thursday. Titan Pharmaceuticals has a one year low of $3.03 and a one year high of $14.80. The firm’s fifty day moving average is $3.45 and its two-hundred day moving average is $4.51.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- How to Calculate Return on Investment (ROI)
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
